Your browser doesn't support javascript.
loading
Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas.
Liu, Emma Munan; Shi, Zhi-Feng; Li, Kay Ka-Wai; Malta, Tathiane M; Chung, Nellie Yuk-Fei; Chen, Hong; Chan, Janice Yuen-Tung; Poon, Manix Fung-Man; Kwan, Johnny Sheung-Him; Chan, Danny Tat-Ming; Noushmehr, Houtan; Mao, Ying; Ng, Ho-Keung.
Afiliação
  • Liu EM; Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Shi ZF; Hong Kong and Shanghai Brain Consortium (HSBC), Hong Kong, China.
  • Li KK; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
  • Malta TM; Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Chung NY; Hong Kong and Shanghai Brain Consortium (HSBC), Hong Kong, China.
  • Chen H; Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan, USA.
  • Chan JY; Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Poon MF; Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
  • Kwan JS; Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Chan DT; Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Noushmehr H; Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Mao Y; Division of Neurosurgery, Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong.
  • Ng HK; Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan, USA.
Brain Pathol ; 32(6): e13107, 2022 11.
Article em En | MEDLINE | ID: mdl-35815721
ABSTRACT
Telomerase reverse transcriptase (TERT) promoter (pTERT) mutation has often been described as a late event in gliomagenesis and it has been suggested as a prognostic biomarker in gliomas other than 1p19q codeleted tumors. However, the characteristics of isocitrate dehydrogenase (IDH) wild type (wt) (IDHwt), pTERTwt glioblastomas are not well known. We recruited 72 adult IDHwt, pTERTwt glioblastomas and performed methylation profiling, targeted sequencing, and fluorescence in situ hybridization (FISH) for TERT structural rearrangement and ALT (alternative lengthening of telomeres). There was no significant difference in overall survival (OS) between our cohort and a the Cancer Genome Atlas (TCGA) cohort of IDHwt, pTERT mutant (mut) glioblastomas, suggesting that pTERT mutation on its own is not a prognostic factor among IDHwt glioblastomas. Epigenetically, the tumors clustered into classic-like (11%), mesenchymal-like (32%), and LGm6-glioblastoma (GBM) (57%), the latter far exceeding the corresponding proportion seen in the TCGA cohort of IDHwt, pTERTmut glioblastomas. LGm6-GBM-clustered tumors were enriched for platelet derived growth factor receptor alpha (PDGFRA) amplification or mutation (p = 0.008), and contained far fewer epidermal growth factor receptor (EGFR) amplification (p < 0.01), 10p loss (p = 0.001) and 10q loss (p < 0.001) compared with cases not clustered to this group. LGm6-GBM cases predominantly showed ALT (p = 0.038). In the whole cohort, only 35% cases showed EGFR amplification and no case showed combined chromosome +7/-10. Since the cases were already pTERTwt, so the three molecular properties of EGFR amplification, +7/-10, and pTERT mutation may not cover all IDHwt glioblastomas. Instead, EGFR and PDGFRA amplifications covered 67% and together with their mutations covered 71% of cases of this cohort. Homozygous deletion of cyclin dependent kinase inhibitor 2A (CDKN2A)/B was associated with a worse OS (p = 0.031) and was an independent prognosticator in multivariate analysis (p = 0.032). In conclusion, adult IDHwt, pTERTwt glioblastomas show epigenetic clustering different from IDHwt, pTERTmut glioblastomas, and IDHwt glioblastomas which are pTERTwt may however not show EGFR amplification or +7/-10 in a significant proportion of cases. CDKN2A/B deletion is a poor prognostic biomarker in this group.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article